Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions

American Journal of Respiratory and Critical Care Medicine

Volumn 163, Issue 5, 2001, Pages 1153-1157

  Zahm, J M ^a   Debordeaux, C ^a   Maurer, C ^a   Hubert, D ^a   Dusser, D ^a   Bonnet, N ^a   Lazarus, R A ^a   Puchelle, E ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; DNA; DORNASE ALFA;

ADULT; ARTICLE; BRONCHUS SECRETION; CELL COUNT; CLINICAL ARTICLE; COUGHING; CYSTIC FIBROSIS; DOSE RESPONSE; ENZYME INHIBITION; FEMALE; FREEZING; HUMAN; INFLAMMATORY CELL; MALE; PRIORITY JOURNAL; PROTEIN DNA BINDING; SURFACE PROPERTY; THAWING; VISCOSITY;

EID: 0035038982     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.163.5.2005002     Document Type: Article

References (24)

1. The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro
2. The composition of pulmonary secretions from patients with and without cystic fibrosis
3. The role of mucous glycoproteins in the rheological properties of cystic fibrosis sputum
4. Reduction of viscosity of cystic fibrosis sputum in vitro by gelsolin
5. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum
6. Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus
7. Emerging therapies for cystic fibrosis lung disease
8. Engineering actin-resistant DNase I for treatment of cystic fibrosis
9. Gelsolin activates DNase I in vitro and cystic fibrosis sputum
10. Actin is the naturally occurring inhibitor of deoxyribonuclease I
11. Engineering hyperactive variants of human deoxyribonuclease I by altering its functional mechanism
12. Hyperactivity of human DNase I variants: Dependence on the number of positively charged residues and concentration, length, and environment of DNA
13. Improved potency of hyperactive and actin-resistant human DNase I variants for treatment of cystic fibrosis and systemic lupus erythematosus
14. Long-term study of one hundred and five patients with cystic fibrosis
15. Elasto-thixotropic properties of bronchial mucus and polymer analogs
16. Automatic measurement of the wetting properties of fluids
17. Clearance of mucus by simulated cough
18. Actin filaments mediate DNA fiber formation in chronic inflammation airway disease
19. Cell death of human polymorphonuclear neutrophils induced by a Pseudomonas aeruginosa cystic fibrosis isolate requires a functional type III secretion system
20. Direct observation of tube-like motion of a single polymer chain
21. Relationship between the lipid content and the rheological properties of airway secretions in cystic fibrosis
22. Improvement of cystic fibrosis airway mucus transportability by recombinant human DNase is related to changes in phospholipid profile
23. Effect of a short course of rhDNase on cough and mucocilairy clearance in patients with cystic fibrosis
24. Sputum pharmacodynamics and pharmacokinetics of recombinant human DNase I in cystic fibrosis